Potential clinical applications of rhGM-CSF in acute myeloid leukemia based on its biologic activity and receptor interaction

Haematologica

Volumn 82, Issue 2, 1997, Pages 239-245

  Lanza, Francesco ^a,b   Rigolin, Gian Matteo ^a   Castagnari, Barbara ^a   Moretti, Sabrina ^a   Castoldi, Gianluigi ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b S ANNA HOSPITAL   (Italy)

Author keywords

Acute myeloid leukemia; Blast cell recruitment; GM CSF receptors; Neutrophil recovery; Peripheral blood progenitor tell transplantation; rhGM CSF

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; REVIEW; TREATMENT INDICATION;

ACUTE DISEASE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOID; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; RECOMBINANT PROTEINS;

EID: 0031435091     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Gasson J. Molecular physiology of granulocyte-macrophage colony stimulating factor. Blood 1991; 6:1131-45.
2. Aglietta M. Haemopoietic growth factors in oncology. An overview. Forum 1991; 1:384-93.
3. Lowenberg B, Touw IP. Haematopoietic growth factors and their receptors in acute leukemia. Blood 1993; 2:281-92.
4. Lieschke GJ, Stanley E, Grail D, et al. Mice lacking both macrophage- and granulocyte macrophage colony-stimulating factor have macrophages and co-existent osteopetrosis and severe lung disease. Blood 1994; 84:27-32.
5. Lowenberg B, De Greef GE, Wielenga JJ. Granulocyte-macrophage colony-stimulating factor in the treatment of haematological malignancies. Anticancer Drugs 1993; 4:17-20.
6. Tafuri A, Andreef M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990; 12:826-34.
7. Buchner T, Hiddermann W, Koenigsmann M, et al. Recombinant human granulocyte macrophage colony stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 1991; 78:1190-7.
8. Baro CR, Bello-Fernandez C, Hermida G, et al. Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) administration after autologous bone marrow transplantation for acute myeloblastic leukemia enhances activated killer cell function and may diminish leukemic relapse. Bone Marrow Transplant 1995; 15: 721-6.
9. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995; 332:1671-7.
10. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo controlled phase III study of granulocyte-macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia. A study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86:457-62.
11. Visani G, Damiani D, Cenacchi A, Baccarani M, Tura S. Granulocyte-macrophage colony stimulating factor in acute non lymphocytic leukemia before and after chemotherapy. Ann Haematol 1991; 63:276-81.
12. Bernell P, Kimby E, Hast R. Recombinant human granulocyte-macrophage colony stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes. A pilot study. Leukemia 1994; 8: 1631-9.
13. Brodsky RA, Bedi A, Jones RJ. Are growth factors leukemogenic? Leukemia 1996; 10:175-7.
14. Estey EH, Dixon D, Kantarjian HM, et al. Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with Ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1990; 75:1766-9.
15. Bassan R, Rambaldi A, Amaru R, Motta T, Barbui T. Unexpected remission of acute myeloid leukemia after GM-CSF. Br J Haematol 1994; 87:835-8.
16. Heil G, Chadid L, Hoelzer D, et al. GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia. Leukemia 1995; 9:3-9.
17. Zittoun R, Mandelli F, de Witte T, et al. Recombinant human granulocyte macrophage colony stimulating factor (GM-CSF) during induction treatment of acute myelogeneous leukemia (AML). A randomized trial from EORTC-GIMEMA cooperative groups [Abstract]. Blood 1994; 84:231.
18. Bhalla K, Holladay C, Arlin Z, Grant S, Ibrado A. M, Jasiok M. Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blast. Blood 1991; 78:2674-9.
19. Powell BL, Wang LM, Gregory BW, Case LD, Kucera GL. GM-CSF and asparaginase potentiate ara-C cytotoxicity in HL-60 cells. Leukemia 1995; 9:405-9.
20. Estey E, Thall PF, Kantarjian H, et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C+daunorubicin. Comparison to patients treated without GM-CSF. Blood 1992; 79:2246-55.
21. Aglietta M, De Felice L, Stacchini A, et al. In vivo effect of granulocyte-macrophage colony-stimulating factor myeloid leukemia cells. Leukemia 1991; 5:979-84.
22. Bettelheim P, Valent P, Andreef M, Tafuri A, Haimi J. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991; 77:700-11.
23. Puntous M, Lacombe F, Dumain P, et al. Treatment of relapsed acute myeloid leukemia using GM-CSF before intensive chemotherapy. Leuk Lymphoma 1993; 12:95-102.
24. Wiley JS, Cebon JS, Jamieson GP, et al. Assessment of proliferative responses to granulocyte-macrophage colony stimulating factor (GM-CSF) in acute myeloid leukemia using a fluorescent ligand for the nucleoside transport. Leukemia 1995; 8:181-5.
25. Witz F, Harousseau JL, Cahn HH, et al. GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukemia [abstract]. Blood 1994; 84:231a.
26. Buchner T, Hiddeman W, Wormann B, et al. Age and karyotype-dependent effect of GM-CSF multiple course priming in AML [abstract]. Blood 1996; 88:214a.
27. Visani G, Tosi P. GM-CSF in the biology and treatment of acute myeloid leukemias. Forum 1994; 4:71-6.
28. Harousseau JL, Wu D. The use of GM-CSF and G-CSF in the treatment of acute leukemias. Leuk Lymphoma 1995; 18:405-12.
29. Hurtado R, Candelaria M, Vargas F, Majluf A, Bolomos F, Labardini J. rHu GM-CSF after high dose chemotherapy in post remission acute leukemia. Stem Cells 1995; 13:112-22.
30. Wormann B, Reuter C, Zuhlsdorf M, Buchner T, Hiddeman W. Experimental basis for the use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with acute myeloid leukemia. Semin Oncol 1994; 6:39-43.
31. Aglietta M, De Vincentiis A, Lanata L, et al. Peripheral blood stem cells in acute myeloid leukemia. Biology and clinical applications [review article]. Haematologica 1996; 81:77-92.
32. Gianni AM, Siena S, Bregni M. Granulocyte-macrophage colony stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; 2: 580-5.
33. Bregni M, Siena S, Di Nicola M, et al. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy. J Clin Oncol 1996; 14:628-35.
34. Metcalf D. Hematopoietic regulators: redundancy or subtlety? Blood 1993; 82:3515-23.
35. Krshimoto T, Kikutani H. Cytokine receptors. In: Schlossman SF, Boumsell L, Gilks W, eds. Leukocyte typing V. White cell differentiation antigens. Oxford: Oxford University Press; 1995. p. 1855-2002.
36. Rapaport AP, Abboud CN, DiPersio JF. Granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor: receptor biology, signal transduction, and neutrophil activation. Blood Rev 1992; 6:43-57.
37. Miyaijma A, Mui ALF, Ogorochi T, Sakamaki K. Receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3, and interleukin-5. Blood 1993; 7:1960-74.
38. Lanza F, Moretti S, Papa S, Malavasi F, Castoldi GL. Report on the Fifth International Workshop on Human Leukocyte Differentiation Antigens, Boston, November 3-7, 1993. Haematologica 1994; 79:374-86.
39. Jubinsky PT, Laurie AS, Nathan DG, Aldepe-Yetz J, Sieff CA. Expression and function of the human granulocyte-macrophage colony-stimulating factor receptor α subunit. Blood 1994; 12:4174-85.
40. Budel LM, Dong F, Lowenberg B, Touw IP. Haematopoietic growth factor receptors. Structure variations and alternatives of receptor complex formation in normal haematopoiesis and in haematopoietic disorders. Leukemia 1995; 9:553-61.
41. Kitamura T, Miyajima A. Structure and function of the receptors for granulocyte-macrophage colony-stimulating factor. In: Schlossman SF, Boumsell L, Gilks W, eds. Leukocyte typing V. White cell differentiation antigens. Oxford:Oxford University Press; 1995. p. 1868-76.
42. Nimer S.D, Uchida H. Regulation of granulocyte-macrophage colony-stimulating factor and interleukin 3 expression. Stem Cells 1995; 13:324-35.
43. Aglietta M, Piacibello W, Sanavio F. Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. J Clin Invest 1989; 83:551-7.
44. Schmid I, Baldwin GC, Jacobs EL et al. Alterations in phenotype and cell-surface antigen expression levels of human monocytes. Differential response to in vivo administration of rhM-CSF or rhGM-CSF. Cytometry 1995; 22:103-10.
45. Wagner JE, Collins D, Fuller S, et al. Isolation of small, primitive human hematopoietic stem cells. Distribution of cell surface cytokine receptors and growth in SCID-HU mice. Blood 1995; 86:512-23.
46. Lanza F, Castoldi G. Large scale enrichment of CD34+ cells by Percoll density gradients. A CML-based study design. In: Wunder E, Sovalat H, Henon PR, Serke S, eds. Hematopoietic stem cells. The Mulhouse manual. Dayton: AlphaMed Press; 1994. p. 255-75.
47. Lanza F, Campana D, Knapp W, et al. Towards standardization in immunophenotyping hematological malignancies. How can we improve the reproducibility and comparability of flow cytometric results? Eur J Histochem 1996; 40:7-14.
48. Poncelet P, George F, Papa S, Lanza F. Quantitation of hemopoietic cell antigens in flow cytometry. Eur J Histochem 1996; 40:15-32.
49. Lanza F, Castagnari B, Rigolin GM, et al. Flow cytometry quantitation of GM-CSF receptors in acute leukemic blasts and normal hemopoietic cells. Submitted.
50. Carlo Stella C, Cazzola M, De Fabritiis P, et al. CD34-positive cells. Biology and clinical relevance. Haematologica 1995; 80:367-87.
51. Stacchini A, Fubini L, Gatti E, et al. In vivo effect of human granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil GM-CSF receptors. Leukemia 1995; 9:665-70.
52. Khwaja A, Carver J, Jones HM, Paterson D, Linch DC. Expression and dynamic modulation of the human granulocyte-macrophage colony-stimulating factor receptor in immature and differentiated myeloid cells. Br J Haematol 1993; 85:254-9.
53. Wognum AW, Westerman Y, Visser TP, Wagemaker G. Distribution of receptors for granulocyte-macrophage colony-stimulating factor on immature CD34+ bone marrow cells, differentiating monomyeloid progenitors, and mature blood cell subsets. Blood 1994; 3:764-74.
54. Lanza F, Rigolin CM, Moretti S, Castoldi GL. Cytofluorimetric analysis of cytokine receptors in blast cells from acute leukemia. Clinical and biological implication. Cancer J 1996; 9:66-70.
55. Estrov Z, Kurzrock R, Talpaz M. Interruption of endogenous growth regulatory networks. A novel approach to inhibition of leukaemia cell proliferation. Exp Clin Med 1993; 3:306-18.
56. Danova M, Rosti V, Mazzini G, et al. Cell kinetics of CD34-positive hematopoietic cells following chemotherapy plus colony-stimulating factors in advanced breast cancer. Int J Cancer 1995; 63: 646-51.
57. Cebon J, Layton J. Measurement and clinical significance of circulating haematopoietic growth factor levels. Curr Opin Haematol 1994; 1:228-34.
58. Gerhartz HH, Marcus R, Delmer A, et al. A randomized phase II study of low dose cytosine arabinoside plus granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes with a high risk of developing leukemia. Leukemia 1994; 1:16-23.
59. Nicola AN, Wycherley K, Boyd AW, Layton J, Cary D, Metcalf D. Neutralizing and nonneutralizing monoclonal antibodies to the human granulocyte-macrophage colony-stimulating factor receptor alpha chain. Blood 1993; 6:1724-31.
60. Decker J, Fiedler W, Samalecos A, Hossfeld K. Absence of point mutations in the extracellular domain of the α subunit of the granulocyte-macrophage colony-stimulating receptor in a series of patients with acute myeloid leukemia. Leukemia 1995; 9:185-8.